RE: Value of A. LI software business18 Jul 2024 14:26
The focus of the Company’s personalised dosing initiatives going forwards will be to expand the capability of the software to support dosing decision making around not only chemotherapeutic agents but GCSF. Both the ongoing PREDICT-ONC study and potential secondary research with DoseMe clients in the US will support this objective. In parallel, the Company is seeking ways to make the blood sampling required by its software more convenient for patients. This can potentially be achieved by using the software in other settings where frequent blood sampling already occurs, but also through exploration of the use of new diagnostic devices that can obtain and analyse blood samples in community or home settings (such at that being developed by our partner company Beyond Blood Diagnostics).
As the Company continues to develop its personalised dosing software, it will actively consider the most appropriate way to ring fence resources for this part of its business. Options under consideration include creation of a dedicated business unit, creation of a wholly owned subsidiary or a joint venture with a party with complementary technology/ capabilities. As further progress is made towards one of these, further updates will be provided accordingly.
Dr Peter Sargent, CEO, commented: “I’m really pleased that we’ve able to progress this initiative and the team are excited to build upon the partnership with DoseMe to further develop our Personalised Oncology Dosing Software”.
Paul Edwards, CEO, DoseMe, commented: “Oncology is one area that will benefit tremendously from precision dosing. The results from the initial research point to constructive data output that will enhance dosing decision and ultimately, make life changing differences for patients.”